Inclusion of key populations in clinical trials of new antituberculosis treatments: Current barriers and recommendations for pregnant and lactating women, children, and HIV-infected persons.
Amita Gupta and colleagues discuss priorities in clinical research aimed at improving tuberculosis prevention and treatment in pregnant women, children, and people with HIV.
Main Authors: | Amita Gupta, Michael D Hughes, Anthony J Garcia-Prats, Katherine McIntire, Anneke C Hesseling |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2019-08-01
|
Series: | PLoS Medicine |
Online Access: | https://doi.org/10.1371/journal.pmed.1002882 |
Similar Items
-
Pharmacokinetics and Drug-Drug Interactions of Abacavir and Lamuvudine Co-administered With Antituberculosis Drugs in HIV-Positive Children Treated for Multidrug-Resistant Tuberculosis
by: Louvina E. van der Laan, et al.
Published: (2021-10-01) -
Barriers to initiation of antiretrovirals during antituberculosis therapy in Africa.
by: Dominique J Pepper, et al.
Published: (2011-05-01) -
Challenges and Barriers to Pregnant Women\'s Nutrition:
Policy Recommendations
by: Kefayat Chaman-Ara, et al.
Published: (2018-05-01) -
Cytokines in antituberculosis immunity
by: M V Zakharova, et al.
Published: (2009-12-01) -
ANTITUBERCULOSIS DRUG DOSAGE FORMS: RANGE, KEY BENEFITS AND PROSPECTS OF TECHNOLOGICAL IMPROVEMENT
by: M. E. Kim, et al.
Published: (2016-09-01)